News and Announcements
OncoSil Pancreatic Cancer Clinical Study Update
- Published November 28, 2016 11:44AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
28th November 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to provide an update on its global OncoPaC clinical study programme.
Highlights
- Johns Hopkins Hospital and MD Anderson Cancer Centre are the leading U.S. centres.
- Investigational Review Board (IRB) process has commenced and is on-going for these two U.S. centres. • Guy’s and St Thomas’ Hospitals, London are the leading UK centres.
- Monash Health has agreed to be the lead Australian centre – ethics submission filed and under review.
To view the full announcement, please click on the button below.